Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 2
1977 1
1978 1
1979 2
1980 2
1981 1
1982 2
1984 1
1985 4
1986 3
1987 2
1988 3
1989 1
1991 1
1993 1
1994 1
1996 1
1997 3
1998 1
1999 1
2000 1
2001 1
2002 2
2003 1
2004 2
2005 2
2006 1
2007 3
2008 1
2009 1
2010 2
2011 2
2012 1
2013 2
2014 1
2015 1
2016 2
2017 1
2018 1
2019 1
2020 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Pfreundschuh M, et al. Among authors: balleisen l. Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. Lancet Oncol. 2008. PMID: 18226581 Clinical Trial.
Acute myeloid leukemia: treatment over 60.
Büchner T, Hiddemann W, Berdel W, Wörmann B, Schoch C, Löffler H, Haferlach T, Schumacher A, Staib P, Balleisen L, Grüneisen A, Rasche H, Aul C, Heyll A, Lengfelder E, Ludwig WD, Maschmeyer G, Eimermacher H, Karow J, Frickhofen N, Hirschmann WD, Sauerland MC; German AML Co-Operative Group. Büchner T, et al. Among authors: balleisen l. Rev Clin Exp Hematol. 2002 Mar;6(1):46-59; discussion 86-7. doi: 10.1046/j.1468-0734.2002.00059.x. Rev Clin Exp Hematol. 2002. PMID: 12060483 Review.
Treatment of older patients with AML.
Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W. Büchner T, et al. Among authors: balleisen l. Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. doi: 10.1016/j.critrevonc.2004.09.010. Epub 2005 Oct 21. Crit Rev Oncol Hematol. 2005. PMID: 16246568 Review.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS. Niederwieser D, et al. Among authors: balleisen l. Ann Hematol. 2023 Mar;102(3):547-561. doi: 10.1007/s00277-023-05087-8. Epub 2023 Jan 25. Ann Hematol. 2023. PMID: 36695874 Free PMC article.
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Büchner T, et al. Among authors: balleisen l. Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. Leukemia. 2016. PMID: 26965440 Clinical Trial. No abstract available.
High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M; SAKK and the German CML Study Group. Hehlmann R, et al. Leukemia. 2020 Aug;34(8):2074-2086. doi: 10.1038/s41375-020-0826-9. Epub 2020 May 7. Leukemia. 2020. PMID: 32382082 Free PMC article.
Subgroup specific therapy effects in AML: AMLCG data.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Balleisen L, Grüneisen A, Aul C, Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N, Kienast J, Giagounidis A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: balleisen l. Ann Hematol. 2004;83 Suppl 1:S100-1. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124694 No abstract available.
Platelet activation by basement membrane collagens.
Balleisen L, Rauterberg J. Balleisen L, et al. Thromb Res. 1980 Jun 1;18(5):725-32. doi: 10.1016/0049-3848(80)90227-3. Thromb Res. 1980. PMID: 7414558 No abstract available.
Abnormal platelet function in Kallmann syndrome.
Pawlowitzki IH, Diekstall P, Miny P, Balleisen L. Pawlowitzki IH, et al. Among authors: balleisen l. Lancet. 1986 Jul 19;2(8499):166. doi: 10.1016/s0140-6736(86)91981-1. Lancet. 1986. PMID: 2873430 No abstract available.
66 results